The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Board of Directors
    • Our Staff & Volunteers
    • The Antibody Society’s Standing Committees
      • Communication & Membership Committee
      • Finance & Audit Committee
      • Initiatives Committee
      • Meetings Committee
    • Sponsors
    • James S. Huston Antibody Science Talent Award
      • JSH Award Criteria
  • Society meetings
    • Antibody Engineering & Therapeutics (US) 2021
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • Meeting reports
      • Keynote presentations
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2021
      • Antibody Engineering & Therapeutics Europe 2020
      • Antibody Engineering & Therapeutics Europe 2019
    • AIRR Community Meetings
    • FOCIS Symposia
    • Society-Funded Meetings
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Student/Post-doctoral Fellow Competitions
    • Discount codes for meeting registration
    • Antibodies in early-stage studies
    • Antibodies in late-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News You Should Know
    • Antibody therapeutics approved or in regulatory review in the EU or US
    • Research Resources
    • Education Resources
  • Career Center
  • Learning Center
    • Upcoming Webcasts
    • Antibody Discovery & Development
    • Adaptive Immune Receptor Repertoires
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Andrew Bradbury, PhD

Andrew Bradbury, PhD

Speaker: Dr. Andrew Bradbury is Chief Scientific Officer of Specifica. His present research interests lie in improving in vitro display technologies in order to make in vitro antibody selection the preferred method to generate highly specific, high affinity antibodies. Within this context he uses next-generation sequencing extensively during library construction and selections, and has developed an antibody selection pipeline that combines phage and yeast display in methods that exploit the advantages of each. He maintains an active interest in technology development as it relates to display methods and antibody engineering.

He was trained in medicine at the universities of Oxford and London, and subsequently practiced medicine for five years (one full time, and four part time) in the UK.  He received his Ph.D. (Cambridge University) in the MRC Laboratory of Molecular Biology under the guidance of César Milstein.  After his Ph.D. he spent 10 years in Italy: three as a post-doctoral fellow in the CNR Institute of Neurobiology, Rome, Italy, where he was involved with cloning antibody genes for use in intra- and inter-cellular immunization; and seven in Trieste, where he was first visiting professor, and subsequently tenured as assistant professor at the International School for Advanced Studies (SISSA, Trieste, Italy).  He moved to Los Alamos National Lab in July 1999, as a research scientist, and became a group leader in 2010. He left LANL in June 2017 to join Specifica (www.specifica.bio), a start-up he founded in 2016 to provide next-generation exclusive phage antibody libraries to the biopharmaceutical and biotechnology industries.

He was a founding member and the first president (2007-2010) of The Antibody Society. He has published 160 articles, including a number of reviews and perspectives on phage display and antibody engineering. He recently published a commentary in Nature calling for changes in the way research antibodies are supplied, arguing that they should be sequenced and expressed recombinantly in order to improve reproducibility.

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • Prof. Victor Greiff’s webinar is now available On Demand! April 5, 2021
  • Preventing severe disease in Covid-19 patients March 16, 2021
  • Antibody Engineering & Therapeutics Europe Poster Competition March 9, 2021

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • Home
  • Privacy & Terms of Use
  • About
  • Board of Directors
  • Advisors
  • Sponsors
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals